Get the Stockscreener App
2.42
0.42%
0.02
Xbiotech Inc stock is traded at $2.42, with a volume of 1,135.
It is up +0.42% in the last 24 hours and down -6.41% over the past month.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
See More
Previous Close:
$2.40
Open:
$2.4
24h Volume:
1,135
Relative Volume:
0.03
Market Cap:
$73.48M
Revenue:
$300.00K
Net Income/Loss:
$-45.54M
P/E Ratio:
-1.62
EPS:
-1.4938
Net Cash Flow:
$-40.21M
1W Performance:
+0.84%
1M Performance:
-6.41%
6M Performance:
+5.70%
1Y Performance:
-18.58%
1-Day Range:
$2.40
$2.4313
1-Week Range:
$2.38
$2.48
52-Week Range:
$2.09
$3.61
Xbiotech Inc Stock (XBIT) Company Profile
Name
Xbiotech Inc
Sector
Industry
Phone
512-386-2900
Address
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
2.41 | 73.17M | 300.00K | -45.54M | -40.21M | -1.4938 |
VRTX
Vertex Pharmaceuticals Inc
|
438.32 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.73 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.13 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.21 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.90 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-19 | Initiated | Piper Jaffray | Overweight |
| Apr-21-17 | Downgrade | Noble Financial | Buy → Hold |
| Jun-28-16 | Reiterated | Noble Financial | Buy |
Xbiotech Inc Stock (XBIT) Latest News
XBIT | XBiotech Inc Insider Trading - Quiver Quantitative
XBIT Should I Buy - Intellectia AI
XBiotech stock (US9840001002): Clinical-stage biotech stays in focus - AD HOC NEWS
XBiotech: Q1 Earnings Snapshot - Stamford Advocate
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XBiotech (NASDAQ: XBIT) trims Q1 2026 loss, holds $115.5M cash and cuts R&D spend - Stock Titan
XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar - TipRanks
TradingKey - TradingKey
Number of shareholders of XBiotech, Inc. – FWB:4XB - TradingView
XBiotech (XBIT) Projected to Post Earnings on Tuesday - MarketBeat
XBIT (XBiotech) reports zero Q1 2020 EPS missing estimates, shares dip 0.78 percent amid investor concern.Post Announcement - newser.com
XBiotech Inc. 2025 Executive Compensation, Board Structure, and Shareholder Ownership Overview - Minichart
Executive pay and governance detailed in XBiotech (NASDAQ: XBIT) 10-K/A - Stock Titan
XBIT (XBiotech) posts 100 percent Q1 2020 EPS miss, falls 0.79 percent on soft investor sentiment.Trader Community Insights - newser.com
XBIT (XBiotech Inc.) reports 100 percent Q1 2020 EPS miss, while shares notch mild gains on upbeat investor sentiment.Dividend Cut Risk - Xã Thanh Hà
XBiotech (XBIT) Stock: Price Action Overview (Smart Money Active) 2026-04-18Verified Analyst Reports - Xã Vĩnh Công
Short Interest in XBiotech Inc. (NASDAQ:XBIT) Grows By 21.3% - MarketBeat
Aug PostEarnings: Is XBiotech Inc part of any major index2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Why is XBiotech (XBIT) Stock underperforming the market | Price at $2.33, Down 0.21%Community Sell Signals - Newser
Insider Buy: Is XBiotech Inc stock risky to hold nowMarket Performance Summary & Capital Efficiency Focused Strategies - baoquankhu1.vn
XBiotech (NASDAQ:XBIT) Stock Passes Below Fifty Day Moving AverageShould You Sell? - MarketBeat
CEO Moves: Is XBiotech Inc likely to announce a buybackShare Buyback & Risk Managed Investment Signals - baoquankhu1.vn
Is XBiotech (XBIT) Stock Worth Holding | Price at $2.38, Up 1.28%IV Percentile - Newser
Winners Losers: Can XBiotech Inc lead its sector in growth2026 Earnings Surprises & Growth Focused Entry Point Reports - baoquankhu1.vn
XBIT Stock Analysis: XBiotech Inc. at $2.34, mild 0.43% dip amid biotech sector activity - Newser
Wolverine World Wide Stock: Navigating Challenges in the Competitive Footwear Sector for Long-Term V - AD HOC NEWS
Published on: 2026-03-31 08:55:40 - baoquankhu1.vn
Are short sellers targeting XBiotech (XBIT) Stock | Price at $2.28, Down 2.15%Trending Buy Opportunities - Newser
Stock List: Research Stocks from Around the World - GuruFocus
XBiotech Inc stock faces biotech sector headwinds amid pipeline uncertainty and market volatility - AD HOC NEWS
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB) - Defense World
If You Invested $1,000 in Xbiotech (XBIT) - Stock Titan
Bearish Setup: Does XBiotech Inc offer margin of safetyWeekly Trade Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Setup Watch: Why is XBiotech Inc stock going down2026 Selloffs & Real-Time Stock Movement Alerts - baoquankhu1.vn
Wolverine World Wide Stock (ISIN: US9840001002) Faces Headwinds Amid Footwear Market Shifts - AD HOC NEWS
XBiotech (NASDAQ:XBIT) Stock Price Passes Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
XBiotech Inc. 2025 Annual Report: Risks, Regulatory Challenges, and Competitive Landscape in True Human™ Antibody Drug Development - Minichart
XBiotech: Q4 Earnings Snapshot - marketscreener.com
XBiotech (NASDAQ: XBIT) details IL‑1α pipeline and cash use - Stock Titan
XBiotech 2025 10-K: $0.0M Revenue, $(1.49) EPS - TradingView
XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Gains Recap: Is Kulicke and Soffa Industries Inc in accumulation or distribution phaseQuarterly Investment Review & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Gainers Report: Can DECK keep up with sector leadersJuly 2025 Snapshot & Comprehensive Market Scan Reports - baoquankhu1.vn
Aug Sentiment: Is XBiotech Inc likely to announce a buybackQuarterly Market Summary & Free Verified High Yield Trade Plans - baoquankhu1.vn
XBIT SEC FilingsXbiotech 10-K, 10-Q, 8-K Forms - Stock Titan
XBIT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does XBiotech Inc. offer margin of safetyJuly 2025 Big Picture & Real-Time Buy Zone Alerts - mfd.ru
What’s next for XBiotech Inc. stockJuly 2025 News Drivers & Reliable Momentum Entry Alerts - mfd.ru
Market Review: Can CASI Pharmaceuticals Inc maintain its current growth rateWeekly Investment Recap & Reliable Price Breakout Alerts - baoquankhu1.vn
XBIT PE Ratio & Valuation, Is XBIT Overvalued - Intellectia AI
XBIT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Xbiotech Inc Stock (XBIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
1.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):